{"title":"Rechallenge of brentuximab vedotin was effective for refractory mycosis fungoides: a case report","authors":"Hikaru Kawahara, Etsuko Okada, Yu Sawada","doi":"10.3389/jcia.2024.12474","DOIUrl":null,"url":null,"abstract":"Mycosis fungoides (MF) is a type of primary cutaneous T-cell lymphoma. The anti-cluster of differentiation (CD) 30 antibody agent, brentuximab vedotin (BV), has recently been developed for specific targets against CD30-expressed tumor cells with high efficacy against various lymphomas. Herein, we present a case of marginally CD30-expressed MF successfully treated with BV rechallenge.","PeriodicalId":508694,"journal":{"name":"Journal of Cutaneous Immunology and Allergy","volume":"20 12","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cutaneous Immunology and Allergy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3389/jcia.2024.12474","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Mycosis fungoides (MF) is a type of primary cutaneous T-cell lymphoma. The anti-cluster of differentiation (CD) 30 antibody agent, brentuximab vedotin (BV), has recently been developed for specific targets against CD30-expressed tumor cells with high efficacy against various lymphomas. Herein, we present a case of marginally CD30-expressed MF successfully treated with BV rechallenge.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
